drugset / Trial / NCT00182520
Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)
Phase 4
Completed
23 enrolled
McMaster University
Hamilton Health Sciences Corporation · collabJanssen-Ortho Inc., Canada · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SRI's are considered first-line treatments for OCD, however many patients continue to have significant symptoms despite an adequate trial of an SRI. Neuroimaging studies have shown that the glutamate neurological system is involved in OCD. This study will test the safety and efficacy of topiramate, a drug, which targets glutamate, in the treatment of OCD, where the OCD has been un-responsive, or partially responsive to regular SRI treatment.
Timeline
- Start
- 2002-01
- Primary completion
- 2019-01
- Completion
- 2019-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topiramate | Small molecule | 25 mg | — |
| Subject | Topiramate | Small molecule | 400 mg | — |